Q3 FY2026
Filed Nov 12, 2026Azitra reports Q3 2026 net loss of $(2,949,779) against $(2,764,528) a year earlier; no revenue line is printed
The filing shows clinical progress (ATR-04 Cohort 1 completed with a recommendation to proceed to Cohort 2; ATR-COSF ex vivo and repeat-dose results), but the quarter's net loss widened from $(2,764,528) to $(2,949,779) and no revenue line is printed. Cash and cash equivalents were $3,750,710 at September 30, 2026, up from $2,068,083 at December 31, 2025.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| General and administrative expenses, Q3 2026GAAP | $1,614,814 | – | – |
| Research and development expenses, Q3 2026GAAP | $1,290,644 | – | – |
| Total operating expenses, Q3 2026GAAP | 2,905,458 | – | – |
| Loss from operations, Q3 2026GAAP | (2,905,458) | – | – |
| Interest income, Q3 2026GAAP | 48,531 | – | – |
| Interest expense, Q3 2026GAAP | nil (printed as a dash) | – | – |
| Change in fair value of warrants, Q3 2026GAAP | nil (printed as a dash) | – | – |
| Other income (expense), Q3 2026GAAP | (92,852) | – | – |
| Total other income (expense), Q3 2026GAAP | (44,321) | – | – |
| Loss before income taxes, Q3 2026GAAP | (2,949,779) | – | – |
| Income tax expense, Q3 2026GAAP | nil (printed as a dash) | – | – |
| Net loss, Q3 2026GAAP | $(2,949,779) | – | – |
| Net loss per share, basic and diluted, Q3 2026GAAP | $(0.29) | – | – |
| Cash and cash equivalents, as of September 30, 2026GAAP | $3,750,710 | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- The release refers to a March 2026 private placement. Institutional investors who participated may invest an additional $5.25 million to $10.5 million through certain financial instruments issued in that transaction once ATR-COSF results are announced. The release describes this as an opportunity, not a completed transaction.
- Common stock rose from 107 to 606 and additional paid-in capital rose from 72,322,319 to 83,142,766 between December 31, 2025 and September 30, 2026, as printed on the balance sheet.
What drove it
- Clinical progress on ATR-04: the company reports completion of Cohort 1 of the Phase 1/2 trial and a safety review committee recommendation to proceed to Cohort 2.
- Trial modification: eligibility was expanded to include patients with KRAS and MEK inhibitor-associated rash, including patients with neurofibromatosis type 1 with rash associated with MEK inhibitors.
- Trial requirements were modified to facilitate recruitment. The company states Cohort 2 is expected to enroll approximately 24 patients receiving once-daily treatment for 28 days.
- ATR-COSF: the company reports positive repeat-dose results showing increased delivery and distribution of recombinant filaggrin domains and improved elasticity in ex vivo human skin, and reports that a single application reduced the appearance of fine lines and wrinkles by approximately 50% after 48 hours in laboratory studies.
- Timing markers: topline data from Cohort 1 are expected in Q4 2026, and initial results from the first-in-human cosmetic study of ATR-COSF are expected by year-end 2026.
Concerns
- Net loss widened from $(2,764,528) to $(2,949,779) year over year, as printed in the condensed statement of operations. The release does not give an explanation for the change.
- Other income (expense) moved from $(628) to $(92,852). The release does not explain this line.
- Net loss per share of $(0.29) compares with $(6.71) a year earlier, while weighted average shares outstanding rose from 411,769 to 10,301,517 as printed. The release does not explain the difference.
- The accumulated deficit reached $(78,745,875) at September 30, 2026.
- The forward-looking statements list risks including enrollment delays, possible failure to timely raise additional required funding, the possibility that holders of instruments from the private placement may not exercise them, and the company's ability to maintain its NYSE American listing.
- The company's cash position is $3,750,710. The release links the additional $5.25 million to $10.5 million investment opportunity to ATR-COSF results, so that funding is not yet assured.
What to watch
- Topline data from Cohort 1 of the ATR-04 Phase 1/2 trial, expected in Q4 2026.
- Enrollment progress for Cohort 2, expected to include approximately 24 patients.
- Initial results from the first-in-human cosmetic study of ATR-COSF, expected by year-end 2026.
- Whether the institutional investors from the March 2026 private placement exercise the financial instruments worth $5.25 million to $10.5 million after ATR-COSF results are announced.
- Operating expense trends in the next filing, since the release does not explain the year-over-year increases in R&D and G&A.
- Whether cash and cash equivalents remain sufficient for planned activities, as the company's sufficiency statement is listed among its forward-looking statements.
Balance sheet and cash flow
- Cash and cash equivalents: $3,750,710 at September 30, 2026, against $2,068,083 at December 31, 2025 (balance sheet, unaudited). The release also states cash and cash equivalents of $3.8 million as of September 30, 2026.
- Total assets: $5,973,593 at September 30, 2026, against $5,025,386 at December 31, 2025.
- Total liabilities: $1,576,096 at September 30, 2026, against $1,224,156 at December 31, 2025.
- Total stockholders' equity: $4,397,497 at September 30, 2026, against $3,801,230 at December 31, 2025.
- Accumulated deficit: $(78,745,875) at September 30, 2026, against $(68,521,196) at December 31, 2025.
- Accounts payable rose from $399,356 to $596,800 and accrued expenses rose from $203,740 to $669,137 between December 31, 2025 and September 30, 2026.
- The insurance premium financing liability and the current financing lease liability were nil at September 30, 2026, against $198,983 and $10,111 at December 31, 2025.
- No operating or investing cash flow statement is included in the filing.
Analysis
Azitra reported a Q3 2026 net loss of $(2,949,779), against $(2,764,528) in the third quarter of 2025, on total operating expenses of 2,905,458 against 2,768,484. Research and development expenses were $1,290,644 against $1,180,078, and general and administrative expenses were $1,614,814 against $1,588,406. The release prints the same lines in rounded prose: R&D of $1.3 million against $1.2 million, G&A of $1.6 million against $1.6 million, and a net loss of $3.0 million against $2.8 million. The statement shows no revenue line for either period, so the report contains no sales figures and no gross margin.
Below the operating line, interest income rose to 48,531 from 4,823, and other income (expense) was $(92,852) against $(628). Total other income (expense) was (44,321) against 3,956, which moved the loss before income taxes to a larger figure than the operating loss. Income tax expense was nil in both periods. Net loss per share was $(0.29) against $(6.71). Weighted average shares outstanding were 10,301,517 against 411,769, as printed, and the release does not explain the difference between the two per-share figures.
On the balance sheet, cash and cash equivalents were $3,750,710 at September 30, 2026, up from $2,068,083 at December 31, 2025. Total assets were $5,973,593 and stockholders' equity was $4,397,497. Total liabilities rose to $1,576,096 from $1,224,156, with accounts payable and accrued expenses both higher. Additional paid-in capital rose to 83,142,766 from 72,322,319, and the accumulated deficit reached $(78,745,875). The filing includes no cash flow statement, so operating cash burn for the quarter is not reported. The release says the March 2026 private placement instruments could bring an additional $5.25 million to $10.5 million once ATR-COSF results are announced, and the company makes that funding contingent on those results.
The clinical updates are the main content of the release. The company reports completion of Cohort 1 of the ATR-04 Phase 1/2 trial, a safety review committee recommendation to proceed to Cohort 2, and an expansion of eligibility to KRAS and MEK inhibitor-associated rash. Cohort 2 is expected to enroll approximately 24 patients on once-daily treatment for 28 days, and topline Cohort 1 data are expected in Q4 2026. For ATR-COSF, the company reports ex vivo results on fine lines, wrinkles and elasticity, with a first-in-human cosmetic study planned and initial results expected by year-end 2026.
The release gives no financial guidance and no prior outlook, so no guidance comparison is possible. Several figures the reader may want are not printed: the prior-quarter column, percentage changes, and cash flow data. Expense growth is printed in dollars but not explained. The verdict is mixed because clinical milestones and a higher cash balance sit alongside a wider net loss and a funding route tied to future data.
Management, verbatim
We were very pleased to report research involving ATR-COSF demonstrating a single application of the product was able to reduce the appearance of fine lines and wrinkles by approximately 50% after 48 hours in laboratory studies, while our optimized formulation improved skin elasticity across every measure tested in a separate study.
Francisco Salva, Chief Executive Officer
The recommendation to advance ATR-04 to Cohort 2 brings us closer to our goal of providing a new treatment option for patients whose debilitating skin rash can disrupt essential therapy.
Francisco Salva, Chief Executive Officer
Importantly, once we announce the ATR-COSF results, institutional investors who participated in our financing earlier this year will have the opportunity to invest an additional $5.25 million to $10.5 million through certain financial instruments issued in that transaction.
Francisco Salva, Chief Executive Officer
Not in the filing
stated, not guessed- Revenue: no revenue line is printed in the filing.
- Gross margin and cost of sales: not reported.
- Prior-quarter (Q2 2026) figures: the statement shows only Q3 2026 and Q3 2025 columns.
- Percentage changes and margins: none are printed for any line.
- Financial guidance: the release provides no revenue, expense or other forward guidance, and no prior outlook was supplied.
- Cash flow statement: operating, investing and financing cash flows are not reported.
- Prior-year cash at September 30, 2025: not printed; the only comparison is December 31, 2025, which is a different period length and is therefore not placed in prior_year.
- Explanation of the increase in R&D and G&A, the change in other income (expense), and the per-share change: the release does not state causes.
- Debt and credit facilities: not reported in the filing.
- Share repurchases and dividends: none reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.